Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $924,000.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 220,000 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total transaction of $924,000.00. Following the completion of the sale, the director directly owned 6,429,863 shares of the company’s stock, valued at $27,005,424.60. This represents a 3.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, January 6th, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.36, for a total transaction of $959,200.00.
• On Tuesday, December 2nd, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.37, for a total value of $961,400.00.

Recursion Pharmaceuticals Stock Up 11.8%

Shares of NASDAQ RXRX opened at $3.98 on Monday. The company has a market cap of $2.07 billion, a price-to-earnings ratio of -2.21 and a beta of 0.95. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average price of $4.45 and a two-hundred day moving average price of $4.91. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.54 and a 12 month high of $12.36.

Analysts Set New Price Targets

RXRX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. Finally, UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $9.40.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently made changes to their positions in RXRX. TD Waterhouse Canada Inc. grew its holdings in shares of Recursion Pharmaceuticals by 64.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth about $31,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Recursion Pharmaceuticals by 97.2% during the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after buying an additional 4,446 shares during the period. Allworth Financial LP boosted its holdings in Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $41,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.